These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20171141)

  • 1. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
    Bose D; Meric-Bernstam F; Hofstetter W; Reardon DA; Flaherty KT; Ellis LM
    Lancet Oncol; 2010 Apr; 11(4):373-82. PubMed ID: 20171141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of adverse effects of anti-VEGF therapy for cancer.
    Kamba T; McDonald DM
    Br J Cancer; 2007 Jun; 96(12):1788-95. PubMed ID: 17519900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
    Ravaud A
    Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    Girardi F; Franceschi E; Brandes AA
    Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    Vaklavas C; Lenihan D; Kurzrock R; Tsimberidou AM
    Oncologist; 2010; 15(2):130-41. PubMed ID: 20139170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX; Cleck JN
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Snider KL; Maitland ML
    Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical resection of renal cell carcinoma after targeted therapy.
    Thomas AA; Rini BI; Stephenson AJ; Garcia JA; Fergany A; Krishnamurthi V; Novick AC; Gill IS; Klein EA; Zhou M; Campbell SC
    J Urol; 2009 Sep; 182(3):881-6. PubMed ID: 19616232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
    Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
    Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    English BC; Price DK; Figg WD
    Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.